An in vitro antiviral evaluation of punicalagin toward influenza A virus.
Anantiviral evaluation of punicalagin toward influenza A virus.
AI Summary
Key Findings
Abstract
OBJECTIVE: Influenza complications are mild to serious, and can cause death in some cases. A great deal of attention has been paid in recent years to the development and use of new antiviral compounds to overcome drug resistance in certain strains of the influenza virus and treat the clinical implications. This study aimed to investigate the antiviral effect of punicalagin and its associated mechanism against influenza A (H1N1) virus. MATERIALS AND METHODS: the ant-influenza activity of punicalagin was studied in Madin-Darby Canine Kidney (MDCK) cells using influenza virus A/Puerto Rico/8/34 (H1N1) (PR8) using Hemagglutinin assay (HA) and 50% tissue culture infective dose (TCID). Then, the inhibition of haemagglutination, virucidal activity, inhibitory effect at different times, replication of viral RNA and expression of viral genes were investigated. RESULTS: Punicalagin could inhibit influenza virus infection with 50% inhibitory concentration (IC) of 3.98μg/ml and selectivity index (SI) value of 6.1. Punicalagin decreased virus titers with an inhibitory effect on virus hemagglutination (p
Affiliation
Fatemeh Javadi-Farsani
External References
- PubMed ID:
- 38952775
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.